Merck & Co.
MRK · NYSE · USD · Healthcare
Price
+16.1% since 20/07/20263 months · High $156.00 (-7.9%) · Low $123.37
What is happening
Merck & Co. has fallen 6% since its 6-week high on 22/09/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayHow deep is the dip?
- from the 6-week high-6.5%
Highest daily price: $153.57 on 22/09/2026 · reference of the assessment
- from the 3-month high-7.9%
Highest daily price in 3 months: $156.00 on 25/08/2026
- from the 52-week high-8.5%
Highest price in 52 weeks: $156.92 (Yahoo)
Marking places no order – it only helps you keep track.
Catalysts
1 h ago- News, last 10 days
- no recent news
- Next earnings
- 29/10/2026 · in 9 days
- Last report
- 04/08/2026 +49.4% vs estimate
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
- Headquarters:
- Rahway, United States
- 52-week range:
- $82.01 – $156.92
- Website:
- merck.com
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
